Literature DB >> 24863573

Mesenchymal stem cells are sensitive to treatment with kinase inhibitors and ionizing radiation.

Nils H Nicolay1, Eva Sommer, Ramon Lopez Perez, Ute Wirkner, Tilman Bostel, Anthony D Ho, Michael Lahn, Jürgen Debus, Rainer Saffrich, Peter E Huber.   

Abstract

INTRODUCTION: Mesenchymal stem cells (MSCs) can regenerate damaged tissues and may therefore be of importance for normal tissue repair after cancer treatment. Small molecule receptor kinase inhibitors (RKIs) have recently been introduced into cancer treatment. However, the influence of these drugs-particularly in combination with radiotherapy-on the survival of MSCs is largely unknown.
METHODS: The sensitivity of human primary MSCs from healthy volunteers and primary human fibroblast cells to small molecule kinase inhibitors of the vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and transforming growth factor β (TGFβ) receptors, as well to inhibitors of c-Kit, was examined in combination with ionizing radiation (IR); cell survival and proliferation were assessed. Expression patterns of different kinase receptors and ligands were investigated using gene arrays.
RESULTS: MSCs were highly sensitive to the tyrosine kinase inhibitors SU14816 (imatinib) and SU11657 (sunitinib), but showed only moderate sensitivity to the selective TGFβ receptor 1 inhibitor LY2109761. Primary adult human fibroblasts were comparably resistant to all three inhibitors. The addition of IR had an additive or supra-additive effect in the MSCs, but this was not the case for differentiated fibroblasts. Proliferation was markedly reduced in MSCs following kinase inhibition, both with and without IR. Gene expression analysis revealed high levels of the PDGF α and β receptors, and lower levels of the TGFβ receptor 2 and Abl kinase. IR did not alter the expression of kinase receptors or their respective ligands in either MSCs or adult fibroblasts.
CONCLUSION: These data show that MSCs are highly sensitive to RKIs and combination treatments incorporating IR. Expression analyses suggest that high levels of PDGF receptors may contribute to this effect.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24863573     DOI: 10.1007/s00066-014-0686-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  42 in total

Review 1.  Perspectives on mesenchymal stem cells: tissue repair, immune modulation, and tumor homing.

Authors:  Hyun Sook Hong; Yeong Hoon Kim; Youngsook Son
Journal:  Arch Pharm Res       Date:  2012-02-28       Impact factor: 4.946

Review 2.  The role of cytokines in the development of normal-tissue reactions after radiotherapy.

Authors:  C Herskind; M Bamberg; H P Rodemann
Journal:  Strahlenther Onkol       Date:  1998-11       Impact factor: 3.621

3.  Glycolysis-related gene induction and ATP reduction during fractionated irradiation. Markers for radiation responsiveness of human tumor xenografts.

Authors:  K Goetze; S S Meyer; A Yaromina; D Zips; M Baumann; W Mueller-Klieser
Journal:  Strahlenther Onkol       Date:  2013-07-06       Impact factor: 3.621

4.  Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood.

Authors:  Wolfgang Wagner; Frederik Wein; Anja Seckinger; Maria Frankhauser; Ute Wirkner; Ulf Krause; Jonathon Blake; Christian Schwager; Volker Eckstein; Wilhelm Ansorge; Anthony D Ho
Journal:  Exp Hematol       Date:  2005-11       Impact factor: 3.084

5.  LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.

Authors:  Davide Melisi; Satoshi Ishiyama; Guido M Sclabas; Jason B Fleming; Qianghua Xia; Giampaolo Tortora; James L Abbruzzese; Paul J Chiao
Journal:  Mol Cancer Ther       Date:  2008-04       Impact factor: 6.261

6.  Bidirectional signaling links the Abelson kinases to the platelet-derived growth factor receptor.

Authors:  Rina Plattner; Anthony J Koleske; Andrius Kazlauskas; Ann Marie Pendergast
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

7.  Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells.

Authors:  Emilia Fransvea; Umberto Angelotti; Salvatore Antonaci; Gianluigi Giannelli
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

8.  Evaluation of tyrosine receptor kinases in the interactions of head and neck squamous cell carcinoma cells and fibroblasts.

Authors:  Larissa Sweeny; Terence M Zimmermann; Zhiyong Liu; Eben L Rosenthal
Journal:  Oral Oncol       Date:  2012-07-13       Impact factor: 5.337

9.  Complete remission of TEL-PDGFRB-induced myeloproliferative disease in mice by receptor tyrosine kinase inhibitor SU11657.

Authors:  Jennifer A Cain; Jay L Grisolano; A Douglas Laird; Michael H Tomasson
Journal:  Blood       Date:  2004-03-25       Impact factor: 22.113

10.  Mesenchymal stem cells in tissue growth and repair.

Authors:  N I Kalinina; V Yu Sysoeva; K A Rubina; Ye V Parfenova; V A Tkachuk
Journal:  Acta Naturae       Date:  2011-10       Impact factor: 1.845

View more
  6 in total

Review 1.  The Therapeutic Potential of Mesenchymal Stromal Cells in the Treatment of Chemotherapy-Induced Tissue Damage.

Authors:  Alexander Rühle; Ramon Lopez Perez; Bingwen Zou; Anca-Ligia Grosu; Peter E Huber; Nils H Nicolay
Journal:  Stem Cell Rev Rep       Date:  2019-06       Impact factor: 5.739

2.  Mesenchymal stem cells are resistant to carbon ion radiotherapy.

Authors:  Nils H Nicolay; Yingying Liang; Ramon Lopez Perez; Tilman Bostel; Thuy Trinh; Sonevisay Sisombath; Klaus-Josef Weber; Anthony D Ho; Jürgen Debus; Rainer Saffrich; Peter E Huber
Journal:  Oncotarget       Date:  2015-02-10

Review 3.  Radio-resistant mesenchymal stem cells: mechanisms of resistance and potential implications for the clinic.

Authors:  Nils H Nicolay; Ramon Lopez Perez; Rainer Saffrich; Peter E Huber
Journal:  Oncotarget       Date:  2015-08-14

4.  Mesenchymal stem cells are sensitive to bleomycin treatment.

Authors:  Nils H Nicolay; Alexander Rühle; Ramon Lopez Perez; Thuy Trinh; Sonevisay Sisombath; Klaus-Josef Weber; Anthony D Ho; Jürgen Debus; Rainer Saffrich; Peter E Huber
Journal:  Sci Rep       Date:  2016-05-24       Impact factor: 4.379

5.  Mesenchymal stem cells maintain their defining stem cell characteristics after treatment with cisplatin.

Authors:  Nils H Nicolay; Ramon Lopez Perez; Alexander Rühle; Thuy Trinh; Sonevisay Sisombath; Klaus-Josef Weber; Anthony D Ho; Jürgen Debus; Rainer Saffrich; Peter E Huber
Journal:  Sci Rep       Date:  2016-01-25       Impact factor: 4.379

6.  Cisplatin radiosensitizes radioresistant human mesenchymal stem cells.

Authors:  Alexander Rühle; Ramon Lopez Perez; Christin Glowa; Klaus-Josef Weber; Anthony D Ho; Jürgen Debus; Rainer Saffrich; Peter E Huber; Nils H Nicolay
Journal:  Oncotarget       Date:  2017-09-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.